Skip to main content
The Oncofertility Consortium

The Oncofertility Consortium

Search Open menu

Search form

Onco_Main_Menu

  • About
    • Find out more about the Oncofertility Consortium

      More
      Dr. Teresa K. Woodruff
      Oncofertility Consortium Vision 2030
      Oncofertility Professional Engagement Network
      Scientific Committees
      Contact Us
  • Resource Browser
    • Explore resources for patients, physicians and educators

      More
      For Patients
      For Health Care Professionals
      For Researchers
      For Educators
      For OPEN Members and Global Partners
  • News
    • The latest from the Oncofertility Consortium

      More
      Newsletter
      Events
      Stories
      Blog
      Give Now
  • Find a Clinic / Center
  • Dialogues
    • Explore Dialogues in Oncofertility

      More
      Dialogues
      Webinars
      Videos
      Books
      Publications
      Surveys

You are here

  1. Home
  2. » Blog
  3. » 2014

Blog Archive: June 2014

List
Visual

Estimates of Young Breast Cancer Survivors at Risk for Infertility in the U.S.

June 24, 2014
Allison Goetsch

Gonadotoxic therapies, such as chemotherapy, used to treat breast cancer can have harmful effects on fertility- they destroy ovarian follicles, or women's reserve of ova, resulting in amenorrhea and/or early menopause. Additionally, many endocrine therapies used to treat breast cancer have indirect effects on fertility, often impairing ovulatory and endometrial function.

Approximately 11% of women diagnosed with breast cancer are under age 45, and one of the largest predictors of infertility after cancer treatment in women is age: 5% of women diagnosed with cancer at age 30, 32% of women diagnosed at age 35, and 80% of women diagnosed at age 40 are infertile after cancer treatment. Women under age 45 have unique survivorship concerns- including the risk of infertility due to cancer treatment.

Current guidelines from both the American Society of Clinical Oncology (ASCO) and the American Society for Reproductive Medicine (ASRM) recommend discussing the impact of cancer treatment on fertility and fertility preservation options with all reproductive-aged patients. These discussions need to take place as early as possible following a cancer diagnosis so there is time to consider all fertility preservation options.

gI_60565_TO-poppy-and-STOIt is unknown how many women in the United States are at risk for loss of fertility following breast cancer treatment. A recently published article by Trivers et al. (2014) in The Oncologist, estimated the number of  breast cancer survivors in the U.S. at risk of infertility for whom fertility preservation education is necessary. Trivers et al. (2014) also estimated the number of at-risk survivors who may desire pregnancy and therefore may benefit from a more in-depth fertility preservation consultation as well.

The study combined data from several different sources:

  • National Program of Cancer Registries (NPCR)
  • National Cancer Institute’s (NCI’s) Surveillance, Epidemiology, and End Results (SEER) program
  • NPCR's 2004 Breast and Prostate Cancer Data Quality and Patterns of Care (PoC) study
  • 2006-2010 National Survey of Family Growth (NSFG)

In the cancer registry data, an average of 20,308 women with breast cancer aged <45 years were diagnosed annually. Based on estimates from PoC data, almost all of these survivors (97%, 19,416 women) were hormone receptor positive or received chemotherapy and would be at risk for infertility. These women should receive information about the impact of treatments on fertility. Estimates based on NSFG data suggest approximately half of these survivors (9,569 women) might want children and could benefit from fertility counseling and fertility preservation.

Trivers et al. (2014) conducted the first study determining that nearly all young women diagnosed with early stage breast cancer will receive therapy and treatment that puts them at risk for infertility, and approximately half of at-risk survivors may be interested in having children in the future. Therefore health care providers should discuss the potential impact of cancer treatment on fertility with all reproductive-aged patients diagnosed with cancer and refer them to a fertility specialist before cancer treatment begins.

Unfortunately, barriers exist which prevent young women diagnosed with early stage breast cancer from receiving the needed information regarding their future fertility. Many survivors have reported not receiving information about how cancer treatment effects fertility and/or available fertility preservation options. Nevertheless, health care providers have a critical role in discussing potential risk of infertility in the context of treatment decision making and determining the patient’s interest in having children. Additionally, financial constraints make it difficult for women to proceed with fertility preservation procedures.  Cancer survivors should have access to and coverage for fertility preservation services given the risk of potential infertility and the subsequent quality-of-life implications. The American Medical Association (AMA) recently released a policy supporting coverage by all insurance companies of fertility preservation techniques for cancer patients requiring treatment that may result in infertility.

In conclusion, Trivers et al. (2014) data showed the importance of and the need for fertility preservation consultations and access to oncofertility specialists among almost all young women diagnosed with breast cancer.

__________________________________________________________________________________

Estimates of Young Breast Cancer Survivors at Risk for Infertility in the U.S.

Katrina F. Trivers, Aliza K. Fink, Ann H. Partridge, Kutluk Oktay, Elizabeth S. Ginsburg, Chunyu Li and Lori A. Pollack

The Oncologist published online June 20, 2014

Read the full article, along with updated information and services, at: http://theoncologist.alphamedpress.org/content/early/2014/06/20/theoncologist.2014-0016 

Categories: 

  • Cancer, Oncofertility, Research

Tags: 

  • AYA, breast cancer, breast neoplasms, clinical research, Fertility Preservation, infertility, Oncofertility, pregnancy, reproductive behavior, Research, Survivorship

Oncofertility Patient Education

June 20, 2014
Allison Goetsch

Oncofertility Clinical Guidelines, Recommendations, & Opinions

June 17, 2014
Allison Goetsch

Oncofertility Decision-Making Publications

June 13, 2014
Allison Goetsch

Oncofertility Decision Tools

June 12, 2014
Allison Goetsch

Watch Now!

June 3, 2014
Brigid Martz Smith

Subscribe for Email Updates

Categories

  • Advocate (73)
  • Cancer (206)
  • Children (32)
  • Cme (5)
  • Communication (16)
  • Conferences (146)
  • Education (90)
  • Ethics (27)
  • Fertility (119)
  • Fertility Preservation (335)
  • General (353)
  • Global Partner (69)
  • In The News (136)
  • Introductions (46)
  • Meetings (78)
  • National Physicians Cooperative (40)
  • Oncofertility (354)
  • Oncofertility Saturday Academy (27)
  • Patient Stories (28)
  • Publication (27)
  • Research (176)
  • Science (44)
  • Virtual Grand Rounds (20)

Blog

  • June 2019 (1)
  • May 2019 (1)
  • April 2019 (1)
  • March 2019 (1)
  • October 2018 (11)
  • September 2018 (5)
  • August 2018 (3)
  • June 2018 (2)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (6)
  • January 2018 (5)
  • December 2017 (3)
  • November 2017 (2)
  • October 2017 (3)
  • September 2017 (1)
  • August 2017 (1)
  • July 2017 (8)
  • June 2017 (8)
  • May 2017 (5)
  • April 2017 (1)
  • March 2017 (5)
  • February 2017 (6)
  • January 2017 (6)
  • December 2016 (6)
  • November 2016 (5)
  • October 2016 (2)
  • September 2016 (2)
  • July 2016 (5)
  • June 2016 (10)
  • May 2016 (8)
  • April 2016 (14)
  • March 2016 (14)
  • February 2016 (14)
  • January 2016 (2)
  • November 2015 (27)
  • October 2015 (15)
  • September 2015 (5)
  • August 2015 (2)
  • July 2015 (2)
  • June 2015 (1)
  • May 2015 (3)
  • April 2015 (5)
  • March 2015 (3)
  • February 2015 (5)
  • January 2015 (2)
  • December 2014 (1)
  • November 2014 (2)
  • October 2014 (3)
  • September 2014 (2)
  • August 2014 (4)
  • July 2014 (4)
  • June 2014 (6)
  • May 2014 (8)
  • April 2014 (4)
  • March 2014 (5)
  • February 2014 (7)
  • January 2014 (3)
  • December 2013 (3)
  • November 2013 (5)
  • October 2013 (7)
  • September 2013 (2)
  • August 2013 (2)
  • July 2013 (4)
  • June 2013 (8)
  • May 2013 (7)
  • April 2013 (7)
  • March 2013 (4)
  • February 2013 (6)
  • January 2013 (4)
  • December 2012 (5)
  • November 2012 (5)
  • October 2012 (11)
  • September 2012 (10)
  • August 2012 (13)
  • July 2012 (8)
  • June 2012 (9)
  • May 2012 (11)
  • April 2012 (10)
  • March 2012 (16)
  • February 2012 (10)
  • January 2012 (13)
  • December 2011 (9)
  • November 2011 (9)
  • October 2011 (11)
  • September 2011 (7)
  • August 2011 (12)
  • July 2011 (10)
  • June 2011 (10)
  • May 2011 (9)
  • April 2011 (9)
  • March 2011 (12)
  • February 2011 (10)
  • January 2011 (10)
  • December 2010 (8)
  • November 2010 (11)
  • October 2010 (13)
  • September 2010 (6)
  • August 2010 (14)
  • July 2010 (15)
  • June 2010 (9)
  • May 2010 (6)
  • April 2010 (4)
  • March 2010 (3)
  • February 2010 (2)
  • January 2010 (7)
  • December 2009 (1)
  • November 2009 (10)
  • October 2009 (8)
  • September 2009 (7)
  • August 2009 (7)
  • July 2009 (27)
  • June 2009 (14)
  • May 2009 (13)
  • April 2009 (3)
  • March 2009 (4)
  • February 2009 (7)

Disclaimer

The contents of the Oncofertility Consortium Blog are for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Oncofertility Consortium

 

Michigan State University

Department of Obstetrics, Gynecology and Reproductive Biology

965 Wilson Road, Room A626B
East Lansing, MI 48824-1316
Phone: 1 (517) 884 6434
Email: oncofert@msu.edu

NOTICE:

Ownership of this website has been transferred from Northwestern University to Michigan State University.
Please note that some site information may be inaccurate while adjustments to reflect this organizational change are made.

Social Media

  • Contact Information |
  • Site Map |
  • Privacy Statement |
  • Site Accessibility
  • Call MSU: 1 (517) 884-6434 |
  • Visit: msu.edu |
  • MSU is an affirmative-action, equal-opportunity employer. |
  • Notice of Nondiscrimination
  • SPARTANS WILL. |
  • © Michigan State University